Seattle Genetics said today its experimental drug for acute myeloid leukemia passed an interim safety review. The Bothell, WA-based biotech company (NASDAQ: [[ticker:SGEN]]) said an independent monitoring committee recommended the study continue of lintuzumab (SGN-33). Full results from the trial, which is two-thirds of the way to its enrollment goal of 210 patients, should be available in the first half of 2010, the company said.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
